Wuxi AppTec to invest $120m in antibody discovery and development lab
Newly private WuXi AppTec has announced plans to invest $120m in a biopharmaceutical development laboratory and clinical-scale manufacturing facility in Shanghai, China.
Newly private WuXi AppTec has announced plans to invest $120m in a biopharmaceutical development laboratory and clinical-scale manufacturing facility in Shanghai, China.
Thermo Fisher will expand its antibody, multiplex RNA, and protein analysis tech offerings through the $1.3bn acquisition of Affymetrix.
Mylan has added six candidates to its biosimilar pipeline through a partnership deal with Momenta Pharmaceuticals.
According to analysts, the vaccine contract manufacturing market is poised for growth, and change, as new players emerge in the East.